However, while these strategies often produce and identify Stat5 inhibitors with low IC50 in cell-free assays, they often display poor efficacy against the native Stat5 protein in cell-based assays and perform poorly in actual in vivo tumor growth studies conducted in animals. This evidence concerns the gene STAT5B and neoplasm.